Assessment of Efficacy and Safety of Kaishora Guggulu and Madhusnuhi Rasayana in the treatment of Vatarakta (Primary Gouty Arthritis

Clinical efficacy and safety of Kaishora Guggulu and Madhusnuhi Rasayana in the management of Vatarakta ( Primary Gouty Arthritis)- A randomized controlled trial - Nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074412

Enrollment

140

Registered

2024-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex aged between 25 and 65 years. 2. Confirmed cases of Primary Gouty arthritis fulfilling the diagnostic criteria as recommended by the American College of Rheumatology (2015), it should meet a threshold score of = 8 classified an individual as having GOUT out of total 23 score 3.3. Willing and consented to participate in the study for 14 weeks.

Exclusion criteria

Exclusion criteria: Any history of trauma, fracture, inflammatory joint diseases,diabertes, CKD, MALIGNANCY, CVD, THYROID DISEASE, HEPATIC DISEASES, ALCOHOLIC, PREGNANCY, LACTATIONG MOTHER

Design outcomes

Primary

Measure	Time frame
Change in pain through VAS scale Timepoint: From baseline to 84 days of the trial	—

Secondary

Measure	Time frame
To observe the clinical efficacy & safety with change in mean percentage of serum uric acid. Timepoint: Baseline to 84 days of trial	—

Countries

India

Contacts

Public ContactDr Purnendu Panda

CCRAS-CENTRAL AYURVEDA RESEARCH INSTITUTE

pandapurnendu02@yahoo.com919777852889

Outcome results